Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures: 2010-2018

Historic Gains from Sales and Divestitures for Vanda Pharmaceuticals (VNDA) over the last 5 years, with Mar 2018 value amounting to $475,367.

  • Vanda Pharmaceuticals' Gains from Sales and Divestitures rose 36.79% to $475,367 in Q1 2018 from the same period last year, while for Mar 2018 it was $475,367, marking a year-over-year increase of 36.79%. This contributed to the annual value of $362,313 for FY2017, which is 25.95% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Gains from Sales and Divestitures of $475,367 as of Q1 2018, which was up 31.20% from $362,313 recorded in Q4 2017.
  • Vanda Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $475,367 during Q1 2018, with a 5-year trough of $209,562 in Q1 2014.
  • Over the past 3 years, Vanda Pharmaceuticals' median Gains from Sales and Divestitures value was $347,504 (recorded in 2017), while the average stood at $337,998.
  • Data for Vanda Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY soared of 37.48% (in 2014) over the last 5 years.
  • Over the past 5 years, Vanda Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $209,562 in 2014, then rose by 10.27% to $231,093 in 2015, then increased by 24.48% to $287,666 in 2016, then climbed by 25.95% to $362,313 in 2017, then surged by 36.79% to $475,367 in 2018.
  • Its Gains from Sales and Divestitures was $475,367 in Q1 2018, compared to $362,313 in Q4 2017 and $356,127 in Q3 2017.